Icares Medicus Inc (6612) - Total Liabilities

Latest as of December 2025: NT$1.21 Billion TWD ≈ $38.17 Million USD

Based on the latest financial reports, Icares Medicus Inc (6612) has total liabilities worth NT$1.21 Billion TWD (≈ $38.17 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset momentum of Icares Medicus Inc to track the company's year-over-year net asset growth rate.

Icares Medicus Inc - Total Liabilities Trend (2017–2025)

This chart illustrates how Icares Medicus Inc's total liabilities have evolved over time, based on quarterly financial data. See Icares Medicus Inc (6612) free cash flow to measure how efficiently the company converts operating cash flow to free cash.

Icares Medicus Inc Competitors by Total Liabilities

The table below lists competitors of Icares Medicus Inc ranked by their total liabilities.

Company Country Total Liabilities
Aluko Co Ltd
KO:001780
Korea ₩527.00 Billion
Yen Sun Technology
TWO:6275
Taiwan NT$2.23 Billion
MegaStudy Co. Ltd
KQ:072870
Korea ₩174.50 Billion
Kamdhenu Limited
NSE:KAMDHENU
India Rs531.83 Million
Curo Holdings Co. Ltd
KQ:051780
Korea ₩60.61 Billion
WTK Holdings Bhd
KLSE:4243
Malaysia RM673.11 Million
Alkim Alkali Kimya AS
IS:ALKIM
Turkey TL1.41 Billion
Maywood Acquisition Corp. 2 Class A Ordinary Share
NASDAQ:MYX
USA $165.57K

Liability Composition Analysis (2017–2025)

This chart breaks down Icares Medicus Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Icares Medicus Inc (6612) market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.04 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.66 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.38 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Icares Medicus Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Icares Medicus Inc (2017–2025)

The table below shows the annual total liabilities of Icares Medicus Inc from 2017 to 2025.

Year Total Liabilities Change
2025-12-31 NT$1.21 Billion
≈ $38.17 Million
-2.71%
2024-12-31 NT$1.25 Billion
≈ $39.24 Million
+419.36%
2023-12-31 NT$239.80 Million
≈ $7.55 Million
+126.98%
2022-12-31 NT$105.65 Million
≈ $3.33 Million
-27.12%
2021-12-31 NT$144.96 Million
≈ $4.57 Million
-0.45%
2020-12-31 NT$145.62 Million
≈ $4.59 Million
+4.75%
2019-12-31 NT$139.02 Million
≈ $4.38 Million
+202.46%
2018-12-31 NT$45.96 Million
≈ $1.45 Million
-29.19%
2017-12-31 NT$64.91 Million
≈ $2.04 Million
--

About Icares Medicus Inc

TWO:6612 Taiwan Medical Instruments & Supplies
Market Cap
$104.55 Million
NT$3.32 Billion TWD
Market Cap Rank
#18968 Global
#1031 in Taiwan
Share Price
NT$70.10
Change (1 day)
+0.43%
52-Week Range
NT$66.50 - NT$115.50
All Time High
NT$185.00
About

ICARES Medicus, Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of ophthalmic medical devices in Taiwan, the United States, United Kingdom, Japan, Spain, China, Germany, and internationally. The company is also involved in the manufacturing, sales, and service of intraocular lenses (IOLs) and its implantation systems for use in treating cataract… Read more